The U.S. Food and Drug Administration announced the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program, giving selected sponsors the option of very rapid review timelines — as fast as one to two months. The initial cohort includes a mix of investigational agents, products already approved abroad and generics, reflecting the program’s broad criteria tied to national priorities such as unmet needs and domestic manufacturing. BioCentury and MedCity reported the list and noted that companies including Disc Medicine, Regeneron and others gained the voucher designation, a development that could accelerate potential approvals and affect market timing for multiple pipelines. The FDA rollout and the commissioner’s selection process were described in agency materials and industry coverage. For developers, the vouchers provide a new regulatory pathway to compress timelines; for competitors and payers, they could shift launch sequencing and commercial planning in late‑stage programs. The vouchers represent an administrative mechanism to prioritize certain reviews and are distinct from existing priority review and breakthrough designations.